We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of ...

Merus (NASDAQ:MRUS – Get Free Report) had its price target hoisted by research analysts at Citigroup from $89.00 to $97.00 in ...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...

In a report released today, Asthika Goonewardene from Truist Financial reiterated a Buy rating on Merus (MRUS – Research Report). The company’s ...

Needham & Company LLC reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $85.00 price target on the ...

Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...

In trading on Monday, shares of Merus NV (Symbol: MRUS) entered into oversold territory, hitting an RSI reading of 29.5, after changing hands as low as $44.16 per share. By comparison, the current ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

In this article, we are going to take a look at where Merus NV (NASDAQ:MRUS) stands against the other promising cancer stocks. According to the World Health Organization (WHO), cancer remains one ...